GSK, the FTSE-100 pharmaceuticals giant, has poached Burberry Group's finance chief to create a rare all-female executive leadership team in London's blue-chip share index. Sky News has learnt that GSK could announce as soon as Monday morning that it has recruited Julie Brown to replace Iain Mackay, who has served as its chief financial officer since 2019. The appointment of Ms Brown comes during a period of seismic change for GSK, which demerged its consumer healthcare business - now called Haleon - in a £30bn deal in July.
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.